Welcome to our dedicated page for Ocular Therapeut SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biotech filings can feel like decoding a clinical protocol—especially when Ocular Therapeutix’s latest 10-K runs hundreds of pages of trial data, cash-runway tables, and FDA milestones. If you have ever Googled “Ocular Therapeutix SEC filings explained simply” or struggled to locate safety endpoints buried deep in an exhibit, this page is built for you.
Stock Titan’s AI reads every new Ocular Therapeutix quarterly earnings report 10-Q filing, Form 8-K material events explained updates, and proxy statement executive compensation tables the moment they hit EDGAR. Our engine produces concise plain-English summaries, highlights pivotal Phase 3 results, and flags liquidity changes—so understanding Ocular Therapeutix SEC documents with AI takes minutes, not hours. Real-time alerts push Ocular Therapeutix Form 4 insider transactions real-time to your dashboard, letting you monitor executive stock transactions Form 4 alongside trial announcements.
Here’s what you can do on this page:
- Track Ocular Therapeutix insider trading Form 4 transactions and option grants before broader market reaction.
- Dive into Ocular Therapeutix earnings report filing analysis without poring over accounting footnotes.
- Access the Ocular Therapeutix annual report 10-K simplified to check cash runway and royalty obligations.
- Set alerts for each Ocular Therapeutix 8-K material events explained, from FDA feedback to partnership deals.
Whether you follow retinal drug developers or just need a clear view of risk factors, our comprehensive coverage—every S-1, 10-Q, 10-K, 4, and DEF 14A—keeps you informed in real time. No more hunting through EDGAR; the critical disclosures investors care about arrive already summarized, searchable, and connected to live market data.
Ocular Therapeutix insider grant summary: Nadia Waheed, the companys Chief Medical Officer, received equity awards on 08/12/2025. She was granted 40,363 restricted stock units (RSUs), each representing a right to one share, which vest over three years in equal annual installments beginning February 11, 2026. She also received a stock option to purchase 122,923 shares at an exercise price of $12.48 per share; the option vests partially (7/48) on September 11, 2025, with the remainder vesting monthly through February 11, 2029, and expires August 11, 2035. Following these transactions, Waheed reports beneficial ownership of 247,168 shares and 122,923 underlying option shares.
Pravin Dugel, Executive Chairman, President and CEO of Ocular Therapeutix (OCUL), reported a series of gift transfers of common stock among family-related parties and an irrevocable trust. On April 28, 2025 he transferred 200,332 shares to his spouse for no consideration and on June 12, 2025 he transferred 50,029 shares to his spouse for no consideration. On August 11, 2025 the spouse transferred 250,361 shares to the "Pravin Dugel 2024 Irrevocable Trust" for no consideration.
The filing states Mr. Dugel is the trustee and sole beneficiary of the Trust during his lifetime and "remains the beneficial owner of the securities held by the Trust." Reported direct beneficial ownership after the June transfer is 3,248,738 shares, and the Trust holds 250,361 shares indirectly.
On 06/11/2025, Ocular Therapeutix (OCUL) Chief Commercial Officer Steve Lawrence Meyers filed a Form 3, establishing his initial beneficial ownership. He directly owns 152,728 common shares, including 117,317 unvested RSUs granted in 2023-2025 under the company’s 2021 Stock Incentive Plan. In addition, Meyers holds four option grants totaling 512,000 shares with strike prices ranging from $3.88 to $7.44 and expirations between 2032-2035; each option vests monthly over four years. The filing is routine, reflects no open-market purchases or sales, and does not alter the company’s capital structure.
Ocular Therapeutix (OCUL) filed a Form 3 disclosing the initial beneficial ownership of its newly appointed Chief Business Officer, Namrata Saroj. The filing reports direct ownership of 200,000 unvested restricted stock units (RSUs) that will vest in three equal annual installments beginning on the first anniversary of her start date.
Derivative holdings include 466,000 stock options spread across three grants: 50,000 options already fully vested at an exercise price of $9.95 expiring 02/27/2034; 100,000 options granted 02/28/2024 at $9.95 vesting 1/48 monthly after an initial one-year cliff; and 316,000 options granted 11/04/2024 at $10.27 with similar four-year vesting. All holdings are reported as direct ownership.
The filing is routine, conveys no operational or financial performance data, and does not imply the insider owns more than 10 % of outstanding shares.
FAQ
What is the current stock price of Ocular Therapeut (OCUL)?
What is the market cap of Ocular Therapeut (OCUL)?
